SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (1192)9/21/1998 10:11:00 PM
From: billy d  Read Replies (1) | Respond to of 10280
 
To Mazen:

Great call on the up move! I will be the first to admit that I never thought it would move up in this market but I'm glad I was wrong!:)

Give me your next call Mr. GURU.

Good luck to all, Billy



To: Ed Ajootian who wrote (1192)9/22/1998 9:36:00 AM
From: Thomas M.  Read Replies (1) | Respond to of 10280
 
IMHO, Phase I & II typically contains primarily safety and dosing trials. Since these two factors have been studied in the lab before, they could rush through these stages. Phase III is probably going to be a bit longer, because improved efficacy is not known scientifically (though it is intuitively likely) and because differentiation with respect to the parent drug is crucial for marketing.

Tom


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News